We injected neuroexcitatory and neuroinhibitory agents into the depressor region of the caudal ventrolateral medulla of anesthetized rabbits and determined the effect on arterial pressure, myocardial contractility, cardiac output, and plasma catecholamines and neuropeptide Y. Brief excitation of the sympathoinhibitory neurons with medullary injection of L-glutamate reduced arterial pressure, peripheral vascular resistance, and myocardial contractility. Cardiac output was unaffected. Prolonged inhibition of the sympathoinhibitory neurons with medullary injection of muscimol increased arterial pressure, peripheral vascular resistance, and myocardial contractility. There was a progressive fall in cardiac output. These changes were accompanied by an increase in plasma neuropeptide Y and plasma norepinephrine, but no change in plasma epinephrine. Our findings indicate that the sympathoinhibitory vasomotor neurons in the caudal ventrolateral medulla tonically suppress the activity of sympathetic preganglionic neurons controlling myocardial contractility as well as peripheral vasomotor tone. Dysfunction of these medullary neurons could underly some forms of experimental hypertension. (Hypertension 1993;21:210-215) KEY WORDS • medulla oblongata • cardiac output • myocardial contraction • rabbit studies A rterial blood pressure increases after interference / \ with the function of sympathoinhibitory vaso-J. \ -motor neurons located in the caudal ventrolateral medulla oblongata (CVLM).
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We injected neuroexcitatory and neuroinhibitory agents into the depressor region of the caudal ventrolateral medulla of anesthetized rabbits and determined the effect on arterial pressure, myocardial contractility, cardiac output, and plasma catecholamines and neuropeptide Y. Brief excitation of the sympathoinhibitory neurons with medullary injection of L-glutamate reduced arterial pressure, peripheral vascular resistance, and myocardial contractility. Cardiac output was unaffected. Prolonged inhibition of the sympathoinhibitory neurons with medullary injection of muscimol increased arterial pressure, peripheral vascular resistance, and myocardial contractility. There was a progressive fall in cardiac output. These changes were accompanied by an increase in plasma neuropeptide Y and plasma norepinephrine, but no change in plasma epinephrine. Our findings indicate that the sympathoinhibitory vasomotor neurons in the caudal ventrolateral medulla tonically suppress the activity of sympathetic preganglionic neurons controlling myocardial contractility as well as peripheral vasomotor tone. Dysfunction of these medullary neurons could underly some forms of experimental hypertension. with the function of sympathoinhibitory vaso-J. \ -motor neurons located in the caudal ventrolateral medulla oblongata (CVLM). 1 -4 Hypertension in the spontaneously hypertensive rat (SHR) may be related to impaired function of these neurons, 5 -7 located between the nucleus ambiguus and the lateral reticular nucleus in the general region containing the Al norepinephrine neurons. Electrolytic lesions of the caudal ventrolateral medulla alter cardiac output and myocardial contractility. 1 -8 However, the lesioning procedure affects fibers of passage and, in addition, significantly increases plasma vasopressin, an effect now recognized to reflect an excitatory effect on the Al cells. 9 -11 When pharmacological agents with a purely inhibitory effect on neuronal cell body function are injected into the CVLM, they increase sympathetic vasomotor tone without increasing plasma vasopressin. 11 Regional blood flow is differentially affected by neurons in the caudal medulla, 12 but so far there is little information concerning how excitation or inhibition of neuronal function in the caudal medulla affects myocardial contractility and cardiac output. The present study examines this question in the anesthetized rabbit. obtaining blood for assay of plasma catecholamines and plasma neuropeptide Y (NPY). In some animals a left ventricular catheter was introduced into the left carotid artery, and the tip was positioned in the left ventricle. The catheter was run subcutaneously to the dorsal cervical region, and the neck wound was closed.
The rabbit, with either Doppler flow transducer or left ventricular catheter in place, was placed in a Kopf stereotaxic frame. The dorsal surface of the medulla oblongata was exposed by incision, retraction of the atlanto-occipital membrane, and removal of the edges of the occipital bone. Neck flexion was adjusted so that the dorsal surface of the medulla was horizontal. The rostral edge of the area postrema in the midline served as the stereotaxic zero for the rostrocaudal and mediolateral coordinates." Injections were made using glass micropipettes with long shanks, and tip diameter was 30 /im. The barrel of the pipette was calibrated in 100-nl steps. The volume injected was always 100 nl and was monitored by observing the movement of the fluid-air meniscus in the barrel of the pipette. Each injection took 2 seconds. Each pipette was left in place for 1 minute after an injection and then withdrawn from the medulla. Subsequent injections at the same site were made by reinserting the pipette at the same coordinates. Neuroactive agents were dissolved in Ringer's solution. At the end of the experiment 100 nl pontamine blue was injected at the same site for histological verification of the injection site. Because the medulla was directly visualized, the injection sites were always observed to be within the vasodepressor area of the caudal ventrolateral medulla (Figure 1 ).
To excite neuronal function in the CVLM we unilaterally injected 0.1-10 nmol monosodium L-glutamate (Sigma). To inhibit neuronal function we bilaterally injected 1-100 nmol -y-aminobutyric acid (GABA, Sigma) or 1 nmol muscimol hydrochloride (Sigma).
Measurement of Circulatory Variables
A strain gauge transducer (model P23ID, Statham Division, Gould Inc., Oxnard, Calif.) connected to a polygraph (model 7, Grass Instrument Co., Quincy, Mass.) was used to record AP. Mean AP was obtained by filtering the phasic signal. Heart rate (HR) was computed with a Grass 7P4F tachograph triggered by the phasic arterial signal. Left ventricular pressure was measured by connecting the specially fabricated catheter to a Millar catheter micromanometer (Millar Inc, Houston, Tex.). This fluid-filled catheter transducer system has a natural resonant frequency of 100 Hz and damping coefficient of 0.6 and is suitable for measuring left ventricular pressure and rate of change of left ventricular pressure (LV dP/dt), 13 derived from the left ventricular pressure signal by a Tektronik AM 501 operational amplifier (Tektronix Inc, Beaverton, Ore.) connected as a differentiator. The LV dP/dt signal was calibrated directly by substituting a triangular wave of known slope into the differentiator. Cardiac output was measured by a Doppler ultrasonic flowmeter (Baker Institute, Melbourne, Australia) with the sensitivity adjusted so that the phasic flow signal was zero at end diastole. This system is known to give reliable measurement of cardiac output in kiloHertz of Doppler shift in rabbits.
14 Total peripheral resistance was calculated in "units" by dividing the mean AP 8 in millimeters of mercury by the cardiac output in kiloHertz. HR was recorded on a beat-to-beat basis by a cardiotachometer (Beckman Instruments Inc., Schiller Park, 111.) triggered by the left ventricular pulse on phasic Doppler flow. Continuous records of phasic and mean AP, HR, high and low gain left ventricular pressure, LV dP/dt, and phasic and mean aortic flow (cardiac output) were displayed on a Gould 2800 biomedical recording system (Gould Inc., Instruments Division, Cleveland, Ohio) or on a Grass model 7 polygraph.
In one rabbit AP, HR, and LV dP/dt changes in response to CVLM injection of L-glutamate and muscimol were measured after cardiac vagal blockade with methylscopolamine (50 Mg/kg i.v. and 25 Mg/kg every 15 minutes).
Plasma Catecholamines and Neuropeptide Y
Arterial blood samples (1.5 ml) were taken into heparinized tubes from the femoral catheter 5 minutes before and 15 and 30 minutes after injection of muscimol (1 nmol) into the CVLM. The volume withdrawn was replaced by an equal volume of heparinized saline (0.9%). The samples were stored on ice before centrifugation at 3,000 rpm for 10 minutes. Plasma supernatant was then stored at -80°C until assay. Plasma catecholamines (norepinephrine and epinephrine) were measured using high-performance liquid chromatography with electrochemical detection with a sensitivity of less than 20 pg/ml. 15 Plasma NPY was measured by radioimmunoassay, 16 and the limit of sensitivity for this assay was 3.0 pg per tube.
Statistical Analysis
All data are expressed as mean±SEM. Statistical analysis was performed on a Macintosh II computer programmed with the statistical package STATVIEW II. Dose-response curves were analyzed by linear regression and by analysis of variance with repeated measures. After injection of muscimol into the medulla, serial temporal changes in cardiovascular variables, plasma NPY, and plasma catecholamines were analyzed by polynomial regression and by analyses of variance with repeated measures. First-or second-order polynomial regression relations were chosen according to the sig-nificance of the residual variance. Post hoc comparisons were assessed using Fisher's protected "t" tests.
Results

Effect of Chemical Excitation of Neurons in the CVLM
Excitation of neuronal function by a unilateral injection of L-glutamate (0.1-10 nmol) into the CVLM produced cardiovascular changes that commenced within seconds of the injection. The maximum effect was observed within approximately 1 minute, and the baselines returned to preinjection values after approximately 5 minutes. L-Glutamate caused dose-dependent decreases in AP, HR, peripheral vascular resistance, and myocardial contractility (Figure 2 ). There was no significant dose-response fall in cardiac output. However, the highest (10 nmol) dose of L-glutamate significantly reduced cardiac output by 0.11 ±0.04 kHz (n=7, p<0.05), albeit by a small amount (approximately 10% of the resting cardiac output). These responses were observed within 1 minute of the L-glutamate injection. In some rabbits («=6), HR was held constant during L-glutamate injection by atrial pacing at a rate just above resting levels. Unilateral injection of L-glutamate (10 nmol) in these animals still caused a decrease in AP, not significantly different from the fall in AP in unpaced rabbits (-36±2 unpaced, -3 1 ±4 mm Hg paced, n=6, paired t test, p>0.05). Similarly, the highest dose of L-glutamate still significantly reduced cardiac output by 0.12 ±0.04 kHz («=6, p<0.05), a reduction not significantly different from the decrease in cardiac output after injection of 10 nmol L-glutamate into the CVLM in unpaced rabbits. After muscarinic blockade with intravenous methylscopolamine, injection of L-glutamate into the CVLM caused falls in AP, vascular resistance, and myocardial contractility of similar magnitude to those observed without vagal blockade. There was no change in HR or cardiac output.
Effect of Chemical Inhibition of Neurons in the CVLM
Inhibition of neuronal function by bilateral injection of GABA (1-100 nmol) into the CVLM altered cardiovascular function, commencing within 1 minute and reaching a maximum after approximately 5 minutes. Parameters returned to preinjection values after approximately 10 minutes. We observed dose-dependent increases in AP, peripheral vascular resistance, and myocardial contractility (Figure 2) . Cardiac output and HR were not significantly altered.
After bilateral injections of muscimol (1 nmol) into the CVLM, there was a progressive marked increase in AP, commencing within 1 minute (Figure 3) . During the first 15-20 minutes the increase in AP was accompanied by a parallel increase in peripheral vascular resistance and myocardial contractility. During the next 10 minutes these parameters decreased a little, but they were still significantly elevated 30 minutes after the muscimol injection. There was no significant change in HR. Cardiac output began to decrease within 1 minute of the muscimol injection and continued to fall during the 30-minute observation period (Figure 3) . After muscarinic blockade with intravenous methylscopolamine, injection of muscimol into the CVLM caused increases in AP, vascular 
FIGURE 2. Line graphs show log dose-response changes in cardiovascular parameters after either bilateral injection of y-aminobutyric acid (GABA) or unilateral injection of L-glutamate into the caudal ventrolateral medulla.
resistance, and myocardial contractility of similar magnitude to those observed without vagal blockade. Cardiac output progressively decreased with no change in HR.
Plasma NPY was substantially increased 15 and 30 minutes after injection of muscimol, and plasma norepinephrine was significantly elevated 15 minutes after injection of muscimol. Plasma epinephrine was not significantly affected by the muscimol injection. These results are summarized in Table 1 . 
FIGURE 3. Line graphs show cardiovascular parameters during the 30 minutes after bilateral injection of muscimol (1 nmol) into the caudal ventrolateral medulla. Top three curves were fitted by second-order polynomial regression and the bottom two by linear regression.
Arterial blood gases and pH were measured before injection of muscimol and at the 15-minute postinjection time point. There were no significant changes of pH, Pco 2 , or Po 2 after the injection of muscimol (control: pH 7.40±0.02, Pco 2 39±2 mm Hg, Po 2 318+32; after muscimol: pH 7.39±0.02, Pco 2 40±2 mm Hg, Po 2 324±41, n=6, all/»0.05).
Discussion
Our results confirm the previous observation of a dose-related fall in AP after injection of L-glutamate into the CVLM and a dose-related rise in AP after 3 confirming the presence of a population of inhibitory cardiovascular neurons in the CVLM. The present study elucidates the peripheral mechanisms of these changes. When the inhibitory neurons are activated, there is a fall in AP and HR accompanied by a fall in myocardial contractility; there is a simultaneous fall in total peripheral vascular resistance so that cardiac output is not changed. Our pacing studies and the experiment with muscarinic blockade show that vagal effects do not play a significant role in the AP and contractility effects induced by injection of L-glutamate into the CVLM. This agrees with previous observations.
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When the inhibitory neurons are themselves inhibited by GABA, there is a dose-related increase in AP, vascular resistance, and myocardial contractility without a change in HR. The increases in peripheral resistance and myocardial contractility were balanced so that cardiac output remained constant. Muscimol is a high affinity agonist at GABA-A receptors, with a long duration of action because the agent is not taken up by GABAergic nerve terminals. Muscimol also increased AP, peripheral vascular resistance, and myocardial contractility without a change in HR. The increase in peripheral vascular resistance was greater than the increase in myocardial contractility, and a progressive decrease in cardiac output was observed.
We have previously demonstrated that injection of muscimol (1 nmol) into the CVLM entirely prevents the cardiovascular actions of similar injections of L-glutamate as well as blocking certain cardiovascular reflexes for at least 30 minutes. 3 The cardiovascular changes observed during the first 15 minutes are likely to be a primary effect of the muscimol-induced loss of the normal, tonically active, CVLM inhibition of cardiovascular function. Arterial blood Po 2 , Pco 2 , and pH were normal at this time. Plasma epinephrine was not significantly increased during the muscimol-induced increase in peripheral resistance and myocardial contractility. We consider it most likely that the increases were mediated via increases in the sympathetic input to the heart and peripheral vessels. The increases were not prevented by muscarinic vagal cardiac blockade. Direct recordings from renal, splanchnic, and lumbar sympathetic nerves have demonstrated reduction in activity with excitation of CVLM neurons and increase in nerve activity with inhibition of CVLM neurons. 3   -12   ' 17 Similarly, the increases in plasma NPY and plasma norepinephrine observed after muscimol injections presumably reflect increases in peripheral sympathetic vasomotor tone.
There remains the possibility that the GABA-and muscimol-induced increases in myocardial contractility were not sympathetically mediated but occurred in response to the increase in peripheral resistance (increase in afterload) or possibly to some change in venous return (change in preload). However, studies have established that peak dP/dt is a robust measure of myocardial contractility unaffected by increases in afterload. 1819 Similarly, changes in preload cannot explain the observed increases in myocardial contractility. Cardiac output must, over time, be equal to venous return. In our present study there was a progressive fall in cardiac output, with no change in cardiac rate. Venous return would therefore have progressively decreased after the muscimol injection, reducing left ventricular preload. This reduction would, if anything, decrease myocardial contractility.
Only one study has measured changes in regional vascular resistance after alteration of neuronal function in the CVLM in anesthetized animals. Willette et al 12 demonstrated in rats that mesenteric, renal, and hind limb vascular resistances all increased with inhibition of CVLM neuronal function. Blood flow in all these beds was reduced, consistent with our finding of a general fall in cardiac output after injection of muscimol into the CVLM. Maeda et al 20 showed that cerebral blood flow decreases during hypotension induced by activation of depressor neurons in the CVLM.
Cardiovascular function has been monitored after recovery from anesthesia in rabbits with electrolytic lesions made in the CVLM. 1 -8 - 21 These animals also exhibited a marked increase in peripheral vascular resistance and myocardial contractility together with a fall in cardiac output. Cardiac failure and florid pulmonary edema were often observed in these animals. The syndrome was related to an increase in plasma vasopressin as well as an increase in peripheral sympathetic activity.
-
21
- 23 The changes in plasma vasopressin were related to irritative effects of the electrolytic lesions. 9 Inhibiting CVLM neurons with muscimol does not increase plasma vasopressin, 11 and therefore this hormone is not involved in the cardiovascular changes observed after muscimol or GABA injections in the present experiments.
The Al catecholamine neurons are probably responsible for the vasopressin changes after alteration of neuronal function in the CVLM. However, evidence indicates that the depressor neurons do not belong to the Al cell population even though the two groups of neurons are located in a similar region of the medulla oblongata. The depressor neurons appear to act by a direct projection to the rostral medulla, inhibiting the sympathoexcitatory neurons by an action on GABA receptors, 3 -24 -26 and the Al cells probably do not project to this region. 3 Experimental increase of AP in the unanesthetized rabbit induces expression of the c-fos protein in a group of neurons, presumably the depressor neurons, in the CVLM, and very few of these cells belong to the Al group. 27 It is not yet known whether specific inhibitory CVLM neurons, possibly located in specific subregions, can alter vasomotor tone in specific sympathetic vascular beds, such as occurs in the case of sympathoexcitatory neurons in the rostral ventrolateral medulla. 28 - 29 The answer to this question will bear on the overall question of the physiological role of the CVLM inhibitory vasomotor neurons. There is a growing consensus that they may constitute the central inhibitory link between baroreceptor inputs to the nucleus tractus solitarius and the sympathetic premotor cells in the rostral ventrolateral medulla. 17.25,26,30-32 Activation of baroreceptors, such as occurs with a rise in AP, causes a reflex, neurally mediated reduction in myocardial contractility. 33 Increases in AP and myocardial contractility after inactivation of the inhibitory CVLM neurons observed in the present study may therefore have some characteristics of the increases in these parameters associated with peripheral baroreceptor denervation. The inhibitory neurons are themselves tonically inhibited by a powerful GABAergic input, as demonstrated by the dramatic fall in peripheral vasomotor tone that follows injection of bicuculline into the CVLM. 3 Inputs using opioid transmitters also appear to inhibit the depressor neurons, whereas angiotensin II-like inputs appear to excite them. 34 - 36 Smith and Barron 5 -7 found that L-glutamate injection into the CVLM causes a larger AP fall in SHR rats than in control rats. Injection of tetrodotoxin into the CVLM caused a greater rise in AP in the SHR rat. Pharmacological blockade of GABA inputs to the sympathoexcitatory neurons in the rostral medulla causes a smaller rise in AP in SHR rats, suggesting that there may be reduced GABAergic input to these neurons in SHR rats. When GABA inputs arising from the CVLM were eliminated by local injection of tetrodotoxin in both SHR and control rats, subsequent injection of bicuculline into the rostral medulla produced similar increases in AP. This suggests that GABA-mediated inhibition, originating from neurons in the CVLM, is not as potent in the SHR rats, and dysfunction of these neurons may therefore contribute to the hypertension that occurs in these animals. There is some evidence that interference with the arterial supply of the ventrolateral medulla causes hypertension in humans. 37 In conclusion, our present study indicates that the CVLM contains neurons whose activity tonically inhibits myocardial contractility as well as peripheral vascular resistance. Malfunction of these inhibitory neurons might be relevant to some forms of hypertension in humans.
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